Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + Carotuximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Carotuximab||TRC105|TRC-105||TGFBR inhibitor (pan) 2||Carotuximab (TRC105) is a monoclonal antibody that binds to endoglin, a TGF beta-1 accessory receptor highly expressed on tumor vessel endothelial cells, blocking signaling essential for angiogenesis and potentially decreasing proliferation of tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||no benefit||Bevacizumab + Carotuximab||Clinical Study||Actionable||In a clinical study, the addition of TRC105 to Avastin (bevacizumab) treatment in renal cell carcinoma patients did not result in improved progression free survival (2.8 mo vs 4.6 mo) when compared to Avastin (bevacizumab) alone (PMID: 28832978).||28832978|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01806064||Phase I||Bevacizumab + Carotuximab||A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma||Completed|
|NCT02664961||Phase II||Bevacizumab + Carotuximab||Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)||Terminated|
|NCT02354612||Phase Ib/II||Axitinib + Carotuximab Carotuximab + Pazopanib Capecitabine + Carotuximab Carotuximab Bevacizumab + Carotuximab||An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy||Completed|
|NCT01727089||Phase II||Bevacizumab Bevacizumab + Carotuximab||Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer||Completed|